Myriad Genetics, Inc. filed a Form 8-K on November 9, 2026, disclosing that its Compensation and Human Capital Committee approved one-time retention stock option awards for three named executive officers on November 6, 2026.

Key Highlights

  • CFO Benjamin R. Wheeler received a retention stock option covering 121,379 shares of common stock.
  • COO Mark S. Verratti received a retention stock option covering 146,933 shares of common stock.
  • CSO Dale Muzzey received a retention stock option covering 92,632 shares of common stock.
  • Exercise price is equal to the closing price of Myriad Genetics common stock on the grant date of November 6, 2026, according to the filing.
  • Cliff vesting occurs on the third anniversary of the grant date, subject to continued service through that date.
  • Option term is ten years, subject to earlier termination under the plan and award agreement.
  • Awards were granted under the Company's 2026 Employee, Director and Consultant Equity Incentive Plan.

Retention Option Awards Approved for Myriad Genetics Executive Officers

According to the filing, the Compensation and Human Capital Committee of Myriad Genetics' Board of Directors approved the Retention Option Awards on November 6, 2026. The company disclosed that the awards were granted "in order to promote the retention and continuity of the Company's leadership as the Company executes on initiatives designed to improve operational efficiencies and financial performance." The awards are described as one-time equity grants made to certain executive officers, including the named executive officers listed in the filing.

The filing states that each award covers shares of common stock with a par value of $0.01 per share, and that the exercise price per share equals the closing price of the company's common stock on the grant date. All three awards vest in full on the third anniversary of the grant date, contingent on each recipient's continued service with the company through that date. The awards are governed by the 2026 Plan and the related stock option agreement, a form of which was filed as Exhibit 10.1 to the Current Report on NASDAQ:MYGN.

The filing further specifies termination treatment: if a recipient's service ends other than by death, disability, or termination for cause, any vested portion of the option generally remains exercisable for three months following termination. Upon a termination for cause, the option terminates immediately regardless of vesting status. The filing also notes that upon a termination of employment, the awards are subject to the terms of each recipient's applicable Severance and Change in Control Agreement with the company.

What Was Disclosed

Myriad Genetics disclosed one-time retention stock option grants to its CFO, COO, and CSO on November 6, 2026, covering 121,379, 146,933, and 92,632 shares respectively, all cliff-vesting on the third anniversary of the grant date under the 2026 Plan.